TY - JOUR
T1 - Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent - A phase II study of the EORTC early clinical trials group
AU - Bruntsch, Uta
AU - Dodion, Pierre
AU - Ten Bokkel Huinink, Wim W.
AU - Hansen, Heine H.
AU - Pinedo, Herbert M.
AU - Hansen, Mogens
AU - Renard, Josette
AU - Van Glabbeke, Martine
PY - 1986
Y1 - 1986
N2 - Fourteen patients with metastatic renal adenocarcinoma without prior chemotherapy were treated with 1,2,4-triglycidylurazol (TGU, NSC-332488), a new triepoxide alkylating agent. TGU was chosen for this study among other triepoxides because of its high antitumour activity in animal models, its relatively good water solubility and the expected favourable therapeutic index. The starting dose was 800 mg/m2 i.v. (600 mg/m2 for patients with prior extensive radiotherapy) every 4 weeks. No objective tumour regression was seen in this favourable group of patients. Leuko- and thrombocytopenia were the most important side-effects. Severe cumulative and prolonged thrombocytopenia was seen. Other toxicities observed were nausea with or without vomiting in all patients and local phlebitis in some.
AB - Fourteen patients with metastatic renal adenocarcinoma without prior chemotherapy were treated with 1,2,4-triglycidylurazol (TGU, NSC-332488), a new triepoxide alkylating agent. TGU was chosen for this study among other triepoxides because of its high antitumour activity in animal models, its relatively good water solubility and the expected favourable therapeutic index. The starting dose was 800 mg/m2 i.v. (600 mg/m2 for patients with prior extensive radiotherapy) every 4 weeks. No objective tumour regression was seen in this favourable group of patients. Leuko- and thrombocytopenia were the most important side-effects. Severe cumulative and prolonged thrombocytopenia was seen. Other toxicities observed were nausea with or without vomiting in all patients and local phlebitis in some.
UR - http://www.scopus.com/inward/record.url?scp=0022481196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022481196&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(86)90168-9
DO - 10.1016/0277-5379(86)90168-9
M3 - Article
C2 - 3743605
AN - SCOPUS:0022481196
SN - 0277-5379
VL - 22
SP - 697
EP - 699
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 6
ER -